The biotechnology sector continues to offer opportunities for those willing to take on risk in the early stages, as was the case with $CRNX, a trade that at one point posted an intraday return of +446.15%. The progress is particularly noteworthy right now in the field of cellular immunotherapy. In that field, Adaptimmune Therapeutics ($ADAP) It stands out for its focus on T-cell therapies targeting solid tumors, a historically complex segment with high potential for disruption.
The market for cell therapies for solid tumors—synovial sarcoma (≈$500M) and other broader cancers such as ovarian cancer (≈$5–10B)—is part of a global market estimated to be between $20,000M and $30,000M by 2030. Its lead candidate, afami-cel, could generate annual revenue of between $50M and $200M if approved. As of October 9, 2025, the stock is trading at $0,2201.
$ADAP's revenue grew exponentially in 2024, rising to $178M from $60M, driven primarily by clinical milestones and collaborations. Even so, the TTM figure reflects a decline of -64% compared to 2024, most likely due to delays in milestone payments.
| Metrics (000s) | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | 65.085 | 178.032 | 60.281 | 27.148 | 6.149 |
| Operating Expenses | 207.271 | 230.371 | 198.319 | 191.113 | 168.395 |
| Net Income | -169.756 | -70.814 | -113.871 | -165.456 | -158.090 |
Source: Financial reports from Adaptimmune Therapeutics plc.
Net losses decreased in 2024 to -$70.8M from -$113.9M in 2023. Even so, operating expenses continue to exceed revenue, which is to be expected given the nature of the company and its clinical stage.
The balance sheet shows some liquidity, although shareholders' equity has been affected by accumulated losses. Total assets as of December 31, 2024: $245.96M, down from $282.62M in 2023, primarily due to collaboration milestones (for example, with GSK) and the company’s own clinical progress.
Current revenue comes primarily from two sources: milestone payments under contracts with partners such as GSK for the development of letetresgene autoleucel (lete-cel), and R&D collaborations tied to progress in clinical trials.
$ADAP is introducing mixed catalysts for the remainder of 2025 and early 2026, following the sale of its main pipeline (TECELRA, lete-cel, afami-cel, and uza-cel) to US WorldMeds for $55M upfront plus up to $30M in milestone payments, announced on July 28, 2025. The transaction allows the company to retain rights to preclinical programs such as PRAME and CD70 and extends its cash runway through 2026, although it reduces short-term revenue.
The $ADAP options market is dominated by call activity, with low put/call ratios suggesting a generally bullish sentiment—typical of speculative biotech stocks following events such as the July 2025 pipeline sale.
The IV is below its historical volatility, indicating moderate expectations for price movement ahead of the upcoming earnings report or a major catalyst. Low put/call ratios (<0.5) reflect greater interest in calls.
The days-to-cover (short interest divided by the average daily volume of 90.01 million shares) is approximately 0.33 days, indicating that short positions could be closed out quickly in the event of a bullish catalyst. Still, a genuine short squeeze seems unlikely in the short term: although the stock has shown extreme swings (+52% on October 8, 2025, due to rumors of partnerships), the relatively low volume and the absence of a massive catalyst limit the potential for an explosive squeeze.
If the rolling BLA submission for lete-cel results in unexpected milestones or positive news in the November earnings report, it could trigger short covering and a temporary rebound in 20-50%, amplified by the beta of 2.49 and the short interest in 11%.
$ADAP remains a speculative bet within cellular immunotherapy: the sale of its main pipeline to US WorldMeds provides financial breathing room and extends its runway through 2026, but it transfers a significant portion of its future value (lete-cel’s BLA, afami-cel’s approval) to a third party. The options market reflects a moderate bullish bias, and the risk of delisting in 2026 remains the key factor to watch, along with the November earnings report.
Spanish 
English 
German 
French